Trials / Completed
CompletedNCT02783976
Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice
A Prospective, Non-Interventional Cohort Study of Approved Sofosbuvir-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 25 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will collect and evaluate information on the safety and efficacy of Sovaldi-based regimens in routine clinical practice in Mexico. The primary objective of this study is to assess the rates of serious adverse events/reactions (SAEs/SADRs) and adverse events/reactions (AEs/ADRs) in adult participants with chronic hepatitis C virus (HCV) infection treated with Sovaldi in routine clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sovaldi | Sovaldi 400 mg tablets administered orally once daily |
Timeline
- Start date
- 2016-10-28
- Primary completion
- 2018-06-20
- Completion
- 2018-06-20
- First posted
- 2016-05-26
- Last updated
- 2018-10-02
Locations
6 sites across 1 country: Mexico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02783976. Inclusion in this directory is not an endorsement.